Second Sight to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York on September 12th
September 05 2017 - 7:00AM
Business Wire
Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second
Sight" or "the Company"), a developer, manufacturer and marketer of
implantable visual prosthetics to provide useful vision to blind
patients, today announced that Dr. Robert Greenberg, Chairman, will
host one-on-one meetings throughout the day with investors and
present at the Rodman & Renshaw 19th Annual Global Investment
Conference as follows:
Date: Tuesday, September 12, 2017 Time: 1:45 p.m. Eastern
Daylight Time Location: Lotte New York Palace Hotel – 455 Madison
Ave, New York, NY 10022
The presentation will be webcast and available following the
live presentation. The webcast can be viewed at:
http://wsw.com/webcast/rrshq27/eyes
Registration is mandatory. For more information about the
conference or to schedule a one-on-one meeting, please contact your
Rodman & Renshaw representative.
About the Argus II Retinal Prosthesis System
Second Sight's Argus II System provides electrical stimulation
that bypasses the defunct retinal cells and stimulates remaining
viable cells inducing visual perception in individuals with severe
to profound Retinitis Pigmentosa. The Argus II works by converting
images captured by a miniature video camera mounted on the
patient's glasses into a series of small electrical pulses, which
are transmitted wirelessly to an array of electrodes implanted on
the surface of the retina. These pulses stimulate the retina's
remaining cells, intending to result in the perception of patterns
of light in the brain. The patient must learn to interpret these
visual patterns, having the potential to regain some visual
function. The Argus II was the first artificial retina to receive
widespread commercial approval, and is offered at approved centers
in Canada, France, Germany, Italy, Russia, Saudi Arabia, South
Korea, Spain, Taiwan, Turkey, United Kingdom, and the U.S.
About the Orion Visual Cortical Prosthesis System
Second Sight, the manufacturer of the Argus II Retinal
Prosthesis System (Argus II), has developed a new device, the
Orion. A proof-of-concept clinical trial demonstrating the
viability of stimulation of the human visual cortex with a
commercially available device from a different manufacturer began
in Q4 2016 at UCLA. First-in-human clinical studies with the Orion
are planned in 2017. Like the Argus II, the idea behind Second
Sight’s Orion is to convert images captured by a miniature video
camera mounted on the patient's glasses into a series of small
electrical pulses. The Orion is designed to transmit these
electrical pulses wirelessly to an array of electrodes implanted on
the surface of the visual cortex, intended to result in the
perception of patterns of light. By bypassing the retina and optic
nerve and directly stimulating the visual cortex, a cortical
prosthesis system has the potential to restore useful vision to
patients completely blinded due to many reasons, including
glaucoma, diabetic retinopathy, or forms of cancer and trauma.
About Second Sight
Second Sight's mission is to develop, manufacture and market
innovative implantable visual prosthetics to enable blind
individuals to achieve greater independence. Second Sight has
developed and now manufactures and markets the Argus® II Retinal
Prosthesis System. Enrollment has been completed in a feasibility
trial to test the safety and utility of the Argus II in individuals
with Dry Age-Related Macular Degeneration. Second Sight is also
developing the Orion™ Visual Cortical Prosthesis to restore some
vision to individuals who are blind due to causes other than
preventable or treatable conditions. U.S. Headquarters are in
Sylmar, California, and European Headquarters are in Lausanne,
Switzerland. For more information, visit www.secondsight.com.
Safe Harbor
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange and Exchange
Act of 1934, as amended, which are intended to be covered by the
"safe harbor" created by those sections. All statements in this
release that are not based on historical fact are "forward looking
statements." These statements may be identified by words such as
"estimates," "anticipates," "projects," "plans," or "planned,"
"seeks," "may," "will," "expects," "intends," "believes," "should"
and similar expressions or the negative versions thereof and which
also may be identified by their context. All statements that
address operating performance or events or developments that Second
Sight expects or anticipates will occur in the future, such as
stated objectives or goals, or that are not otherwise historical
facts, are forward-looking statements. While management has based
any forward looking statements included in this release on its
current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent
risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements, as a
result of various factors including those risks and uncertainties
described in the Risk Factors and in Management's Discussion and
Analysis of Financial Condition and Results of Operations sections
of our Annual Report on Form 10-K as filed on March 16,
2017, and our other reports filed from time to time with
the Securities and Exchange Commission. We urge you to
consider those risks and uncertainties in evaluating our
forward-looking statements. We caution readers not to place undue
reliance upon any such forward-looking statements, which speak only
as of the date made. Except as otherwise required by the federal
securities laws, we disclaim any obligation or undertaking to
publicly release any updates or revisions to any forward-looking
statement contained herein (or elsewhere) to reflect any change in
our expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is
based.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170905005340/en/
Institutional InvestorsIn-Site Communications, Inc.Lisa
Wilson, 212-452-2793Presidentlwilson@insitecony.comorIndividual
InvestorsMZ North AmericaGreg Falesnik, 949-385-6449Managing
Directorgreg.falesnik@mzgroup.us
Second Sight Medical Pro... (NASDAQ:EYES)
Historical Stock Chart
From Apr 2024 to May 2024
Second Sight Medical Pro... (NASDAQ:EYES)
Historical Stock Chart
From May 2023 to May 2024